Pulmonary fibrosis in a patient treated with erlotinib

Onkologie

Volumn 29, Issue 7, 2006, Pages 342-343

  Bach, Jan Philipp ^a   Kiessling, Andreas M ^a   Kleinhans, Antje ^a   Faoro, Charis ^a   Görg, Christian ^a   Riera Knorrenschild, Jorge ^a   Schwella, Nimrod ^a   Wagner, Hans Joachim ^a   Neubauer, Andreas ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ERLOTINIB; NAVELBINE; PACLITAXEL; STEROID;

ADULT; CANCER RELAPSE; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; HUMAN; LETTER; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MALE; PARESTHESIA; POLYNEUROPATHY;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; PULMONARY FIBROSIS; QUINAZOLINES;

EID: 33745791755     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093663     Document Type: Letter

References (3)

1. Tammaro KA, Baldwin PD, Lundberg AS: Case report: interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). J Oncol Pharma Pract 2005;11:127-130.
2. www.fda.gov/cder/foi/label/2004/021743lbl.pdf
3. Giaccone G: The role of EGFR-TK inhibition in non-small cell lung cancer. Onkologie 2005;28:619-620.